Mediwound Ltd is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Mediwound Ltd in the market include companies such as Vericel Corporation, Organogenesis Holdings Inc., and Avita Medical Ltd. These companies also specialize in advanced wound care treatments and products, providing competition for Mediwound in the industry. However, Mediwound has established a strong presence with its innovative product, NexoBrid, which offers a unique enzymatic debridement therapy. With its effective and efficient wound debridement solution, Mediwound remains a prominent player in the market, even amidst competition from these companies.

MediWound Ltd is a leading biopharmaceutical company specializing in innovative therapeutics for acute and chronic wound healing. Founded in 2001, the company's mission is to provide advanced treatments that help patients' wounds heal faster and more effectively. With a focus on developing and commercializing innovative products, MediWound has built a strong reputation in the medical field. Their flagship product, NexoBrid, is an enzymatic debriding agent approved for treating severe burns. MediWound has a dedicated team of experts and continues to expand its product portfolio to address unmet medical needs in wound care. This commitment has made them a trusted name in the industry.

Mediwound Ltd has achieved several significant milestones. Notably, the company successfully developed NexoBrid, a topically-administered enzymatic debridement agent for the removal of dead tissue in severe burns. In 2014, NexoBrid received marketing approval in Europe, marking a major accomplishment. Additionally, Mediwound Ltd secured marketing authorization from the US FDA in 2020, allowing them to commercialize NexoBrid in the United States. The company has also performed numerous clinical trials, demonstrating the safety and efficacy of their products. With these achievements, Mediwound Ltd has established itself as a pioneering leader in advanced wound care solutions.

Mediwound Ltd is primarily present in Israel, where its headquarters are located. As a biopharmaceutical company, Mediwound focuses on the development and commercialization of novel therapies for severe burns and chronic wound management. It operates globally, expanding its presence through partnerships and collaborations with leading healthcare institutions, organizations, and distributors. With a strong emphasis on innovation, Mediwound aims to provide advanced solutions and improve patients' quality of life worldwide.

Mediwound Ltd is a renowned company that embodies key values and a strong corporate philosophy. With a focus on innovation, Mediwound is committed to developing cutting-edge therapeutic solutions for severe burns, chronic wounds, and other challenging conditions. The company places great importance on integrity, transparency, and ethical practices, ensuring that patients and healthcare professionals can trust their products and services. Mediwound's dedication to quality, combined with a patient-centric approach, fosters long-term relationships and positions the company as a reliable leader in the medical industry. Through continuous research and development, Mediwound Ltd remains dedicated to improving patient outcomes and enhancing the quality of life for individuals worldwide.

Analysts currently set an average price target of 32,13 USD for the Mediwound stock (median: 32,64 USD), implying +123,3 % versus the latest price. The consensus is based on 12 analyst ratings.

Mediwound Analyytikkojen kursstavoitteet 2026

12 analysts currently rate the Mediwound stock: 11 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Mediwound to generate revenue of 24,13 M USD and earnings per share of −2,31 USD.

Mediwound Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Mediwound share trades at 12,36 EUR (14,27 USD).

The Mediwound share (MDWD) is listed on 2 stock exchanges, including: NASDAQ (MDWD), Frankfurt (M8W.F).

MediWound Ltd is an innovative biopharmaceutical company based in Israel, focusing on the development and marketing of advanced wound care therapies. The company offers various products and services, including the well-known MEDICOL Gel, NexoBrid, and other wound treatment products. NexoBrid is a unique enzymatic product that swiftly and effectively removes burned skin. It has proven to be safe and effective in treating severe thermal injuries and has been successfully tested in multiple clinical studies. The product is approved in both Europe and the United States and is successfully marketed worldwide. MEDICOL Gel is a scientifically advanced hydrogel specifically designed for wound care. It utilizes innovative technology for moisture regulation and pain relief and promotes rapid wound healing. The gel is an essential component of wound care and has been proven effective and safe in numerous clinical studies. Additionally, MediWound also offers other products, including TelfaClear, an innovative transparent dressing material that works excellently for wound treatment, and Curabond, a strong and flexible wound adhesive particularly suitable for post-surgical wound care. MediWound aims to revolutionize wound care and improve the quality of life for people worldwide. The company has an experienced leadership team and a strong network of partners in the medical industry. It is supported by a dedicated team of researchers, scientists, and physicians, working closely with leading universities and medical institutions to develop innovative solutions for wound healing. MediWound's business model is based on the development and marketing of advanced wound care therapies. The company focuses on researching and developing new products and services and collaborates closely with customers and partners to ensure its products meet the needs of patients. MediWound's commitment to innovation and excellence has earned it a strong presence in the medical industry. It has formed partnerships with leading companies in the field and also works closely with government agencies and medical facilities to distribute its products worldwide. Overall, MediWound is a leading biopharmaceutical company focusing on the development and marketing of innovative wound care therapies. With its strong partnerships, highly skilled employees, and innovative capabilities, the company is well positioned to revolutionize the wound care market in the future.

odotettu liikevaihto Mediwound on 24,13 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Mediwound on −29,64 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Mediwound:n hinta-voitto-suhde (P/E) on tällä hetkellä −6,17. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Mediwound-osakkeen arvostusta.

Mediwound:n hinta-myynti-suhde (P/S) on tällä hetkellä 7,59. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Mediwound-osakkeen arvostuskennuslukuna.

Mediwound:n Eulpool-laatuscore on 2/10.

Mediwound:n ISIN on IL0011316309. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Mediwound:n WKN on A110TG. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Mediwound:n ticker on MDWD. Tämä pörssinoteeraus käytetään Mediwound-osakkeiden kauppaan pörssissä.

Mediwound maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Mediwound kuuluu sektoriin 'Terveydenhuolto'.

Mediwound:n osingot jaetaan valuutassa USD.